Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- No Approach from Sawai Since December: Kyorin
February 14, 2011
- MTPC Found to Have Omitted Voluntary Stability Studies as Well
February 14, 2011
- Pharmarise Dispenses Increasing Number of Generics
February 14, 2011
- Quick Answer Required on Efficacy of Dasen
February 14, 2011
- Mr Urushibata to Resign as JPhA Councilor
February 14, 2011
- Initial Sales of Kissei's EPO Biosimilar Disappointing
February 14, 2011
- AZ to Apply for 4 NMEs by 2016 in Japan
February 14, 2011
- JPhA Calls on Members to Settle Prices by End of March
February 14, 2011
- Generics' Share Up to 22.4% in 1st Qtr FY2010
February 14, 2011
- Shionogi Starts PIII Trial for 572-Trii
February 14, 2011
- Korosho Lists Unapproved Indications Covered by Health Insurance
February 14, 2011
- Astellas Prepares Applications for 2 Products, Discontinues Development of 6
February 14, 2011
- Otsuka to Start PII Trial of OCV-101 for Pancreatic Cancer
February 14, 2011
- PhRMA to Call For Full Introduction of Premium for Development of New Drugs: Mr Umeda
February 14, 2011
- Gov't to Accept Court-Proposed Compromise in Lawsuit over Hepatitis B
February 14, 2011
- Bayer, Regeneron Start PIII Trial of VEGF Trap-Eye in mCNV in Japan
February 14, 2011
- Approval of Norspan Withheld to Ensure Proper Use: Prof. Ogawa
February 14, 2011
- Sekisui Begins Diagnostics Business Acquired from Genzyme
February 14, 2011
- PIII Trial Confirms Long-Term Safety Profile of Latuda
February 14, 2011
- It Was Necessary to Invite Comments from Public on Approval of NorLevo: Korosho
February 14, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…